Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations

Genetics in Medicine

Volumn 17, Issue 8, 2015, Pages 610-620

  Evenepoel, Lucie ^a,b,c   Papathomas, Thomas G ^b   Krol, Niels ^b   Korpershoek, Esther ^b   De Krijger, Ronald R ^b,d   Persu, Alexandre ^a   Dinjens, Winand N M ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c DE DUVE INSTITUTE   (Belgium)

^d REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

genetics; immunohistochemistry; paragangliomas; pheochromocytomas; succinate dehydrogenase

Indexed keywords

SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE A; SUCCINATE DEHYDROGENASE AF2; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE C; SUCCINATE DEHYDROGENASE D; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CARCINOGENICITY; CATALYSIS; EPIGENETICS; FRAMESHIFT MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN GENOME; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MISSENSE MUTATION; NEUROBLASTOMA; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMATIC REVIEW; THYROID CARCINOMA; UTERUS MYOMA; ANIMAL; ENZYMOLOGY; GENETICS; NEOPLASM;

ANIMALS; GERM-LINE MUTATION; HUMANS; NEOPLASMS; SUCCINATE DEHYDROGENASE;

EID: 84938677284     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.162     Document Type: Article

References (82)

1. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851
2. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009; 325: 1139-1142
3. Ghezzi D, Goffrini P, Uziel G, et al. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet 2009; 41: 654-656
4. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54
5. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26: 268-270
6. Burnichon N, Brière JJ, Libé R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010; 19: 3011-3020
7. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-Associated heritable paraganglioma. Am J Hum Genet 2004; 74: 153-159
8. Xekouki P, Stratakis CA. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocr Relat Cancer 2012; 19: C33-C40
9. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16: 79-88
10. Tomlinson IP, Alam NA, Rowan AJ, et al.; Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-410
11. Castro-Vega LJ, Buffet A, De Cubas AA, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet 2014; 23: 2440-2446
12. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773
13. Schaap FG, French PJ, Bovée JV. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. Adv Anat Pathol 2013; 20: 32-38
14. Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF, Yao YG. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 2010; 402: 378-383
15. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 2011; 17: 641-649
16. Desideri E, Vegliante R, Ciriolo MR. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer Lett 2014; doi: 10.1016/j.canlet.2014.02.023 e-pub ahead of print 12 March 2014
17. Alston CL, Davison JE, Meloni F, et al. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet 2012; 49: 569-577
18. Levitas A, Muhammad E, Harel G, et al. Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase. Eur J Hum Genet 2010; 18: 1160-1165
19. Bourgeron T, Rustin P, Chretien D, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995; 11: 144-149
20. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat 2011; 32: 557-563
21. Wang K, Li MY, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res 2010; 38: e164
22. Wildeman M, van Ophuizen E, den Dunnen JT, Taschner PE. Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker. Hum Mutat 2008; 29: 6-13. Accessed 1 April, 2014
23. National Center for Biotechnology Information. Chapter 18, The Reference Sequence (RefSeq) Project. http://www.ncbi.nlm.nih.gov/books/NBK21091. National Library of Medicine: Bethesda, MD, 2002
24. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000; 15: 7-12
25. Altshuler DM, Durbin RM, Abecasis GR, et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012; 491: 56-65
26. National Center for Biotechnology Information. Database of Single Nucleotide Polymorphisms (dbSNP). National Library of Medicine: Bethesda, MD
27. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014; 42(Database issue): D980-D985
28. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue): D945-D950
29. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-874
30. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249
31. Reva B, Antipin Y, Sander C. Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol 2007; 8: R232
32. González-Pérez A, López-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 2011; 88: 440-449
33. Kircher M, Witten DM, Jain P, ORoak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014; 46: 310-315
34. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10: 764-771
35. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011; 96: E1472-E1476
36. Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 2012; 97: E954-E962
37. Letouzé E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23: 739-752
38. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 2009; 266: 19-42
39. Gimenez-Roqueplo AP, Favier J, Rustin P, et al.; COMETE Network. Mutations in the SDHB gene are associated with extra-Adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63: 5615-5621
40. King KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 2011; 29: 4137-4142
41. Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 2013; 37: 234-240
42. Doyle LA, Hornick JL. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology 2014; 64: 53-67
43. Srigley JR, Delahunt B, Eble JN, et al.; ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of renal neoplasia. Am J Surg Pathol 2013; 37: 1469-1489
44. Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 2014; e-pub ahead of print 18 July 2014.doi: 10.1038/modpathol.2014.86
45. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014; e-pub ahead of print 14 July 2014
46. Papathomas TG, Gaal J, Corssmit EP, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenaserelated PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol 2014; 170: 1-12
47. Gill AJ, Toon CW, Clarkson A, et al. Succinate dehydrogenase deficiency is rare in pituitary adenomas. Am J Surg Pathol 2014; 38: 560-566
48. Dwight T, Benn DE, Clarkson A, et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 2013; 37: 226-233
49. Italiano A, Chen CL, Sung YS, et al. SDHA loss of function mutations in a subset of young adult wild-Type gastrointestinal stromal tumors. BMC Cancer 2012; 12: 408
50. Belinsky MG, Rink L, von Mehren M. Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol 2013; 3: 117
51. Dwight T, Mann K, Benn DE, et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2013; 98: E1103-E1108
52. Mensenkamp AR, van Gassen K, Kusters B, Kunst DH, Bongers MHF, Lenders JWM. Prevalence of SDHA mutations and associated clinical spectrum among patients with pheochromocytomas, extra adrenal paragangliomas and glomus tumors. Paper presented at ENSAT Meeting, Budapest, Hungary, 22-23 November 2013
53. Malinoc A, Sullivan M, Wiech T, et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr Relat Cancer 2012; 19: 283-290
54. Tenorio Jiménez C, Izatt L, Chang F, Moonim MT, Carroll PV, McGowan BM. Carney Stratakis syndrome in a patient with SDHD mutation. Endocr Pathol 2012; 23: 181-186
55. Sjursen W, Halvorsen H, Hofsli E, et al. Mutation screening in a Norwegian cohort with pheochromocytoma. Fam Cancer 2013; 12: 529-535
56. Pantaleo MA, Astolfi A, Indio V, et al. SDHA loss-of-function mutations in KIT-PDGFRA wild-Type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst 2011; 103: 983-987
57. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013; 26: 289-294
58. Belinsky MG, Rink L, Flieder DB, et al. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-Type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 2013; 52: 214-224
59. Celestino R, Lima J, Faustino A, et al. A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Fam Cancer 2012; 11: 189-194
60. Oudijk L, Gaal J, Korpershoek E, et al. SDHA mutations in adult and pediatric wild-Type gastrointestinal stromal tumors. Mod Pathol 2013; 26: 456-463
61. Grogan RH, Pacak K, Pasche L, Huynh TT, Greco RS. Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. J Clin Oncol 2011; 29: e200-e202
62. Weber A, Hoffmann MM, Neumann HP, Erlic Z. Somatic mutation analysis of the SDHB, SDHC, SDHD, and RET genes in the clinical assessment of sporadic and hereditary pheochromocytoma. Horm Cancer 2012; 3: 187-192
63. Habano W, Sugai T, Nakamura S, et al. Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol Rep 2003; 10: 1375-1380
64. Carney JA. Carney triad. Front Horm Res 2013; 41: 92-110
65. Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 2014; 21: 567-577
66. Piruat JI, Pintado CO, Ortega-Sáenz P, Roche M, López-Barneo J. The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 2004; 24: 10933-10940
67. Bayley JP, van Minderhout I, Hogendoorn PC, et al. Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS One 2009; 4: e7987
68. Millán-Uclés A, Díaz-Castro B, García-Flores P, et al. A conditional mouse mutant in the tumor suppressor SdhD gene unveils a link between p21(WAF1/Cip1) induction and mitochondrial dysfunction. PLoS One 2014; 9: e85528
69. Hoekstra AS, Bayley JP. The role of complex II in disease. Biochim Biophys Acta 2013; 1827: 543-551
70. Goldstein AM. Germline BAP1 mutations and tumor susceptibility. Nat Genet 2011; 43: 925-926
71. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42: 454-458
72. Gaujoux S, Tissier F, Ragazzon B, et al. Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association. J Clin Endocrinol Metab 2011; 96: E1888-E1895
73. Oishi Y, Nagai S, Yoshida M, et al. Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene. Endocr J 2010; 57: 745-750
74. Cadiñanos J, Llorente JL, de la Rosa J, et al. Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma. Head Neck 2011; 33: 1233-1240
75. Hes FJ, Weiss MM, Woortman SA, et al. Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med Genet 2010; 11: 92
76. Solis DC, Burnichon N, Timmers HJ, et al. Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clin Genet 2009; 75: 354-363
77. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014; 14: 108-119
78. van Nederveen FH, Korpershoek E, Lenders JW, de Krijger RR, Dinjens WN. Somatic SDHB mutation in an extraadrenal pheochromocytoma. N Engl J Med 2007; 357: 306-308
79. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000; 60: 6822-6825
80. Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 2013; 3: 648-657
81. Neumann HP, Pawlu C, Peczkowska M, et al.; European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292: 943-951
82. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91: 827-836